TGTX - TG Therapeutics, Inc.
| Previous Close | 7.12 |
| Open | 7.00 |
| Bid | 7.20 x 800 |
| Ask | 7.43 x 800 |
| Day's Range | 7.00 - 7.51 |
| 52 Week Range | 3.32 - 16.00 |
| Volume | 2,506,926 |
| Avg. Volume | 2,391,488 |
| Market Cap | 614.129M |
| Beta (3Y Monthly) | 1.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.71 |
- CNBC Videos•3 days ago
TG Therapeutics CEO: Going through the process to reach big markets
Jim Cramer catches up with TG Therapeutics CEO Michael Weiss in the wake of its latest earnings report.
- Thomson Reuters StreetEvents•yesterday
Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT
Q1 2019 TG Therapeutics Inc Earnings Call
- GlobeNewswire•10 days ago
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
NEW YORK, May 16, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 55th American Society of Clinical Oncology.
Motley Fool•16 days agoTG Therapeutics Inc (TGTX) Q1 2019 Earnings Call Transcript
TGTX earnings call for the period ending March 31, 2019.
- Associated Press•16 days ago
TG Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 43 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•16 days ago
TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
NEW YORK, May 10, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2019 and recent company developments..
- GlobeNewswire•17 days ago
TG Therapeutics to Host Conference Call on First Quarter 2019 Financial Results and Business Update
NEW YORK, May 09, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, May 10, 2019 at 8:00 AM ET to discuss results for.
- GlobeNewswire•19 days ago
TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced the presentation of long-term follow-up data from the Phase 2 and Open Label Extension (OLE) trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data are being presented today at the American Academy of Neurology 71st Annual Meeting taking place in Philadelphia, PA.
- Zacks•last month
Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.
- Motley Fool•last month
Is TG Therapeutics a Buy?
The stock price of this clinical-stage biotech has nearly doubled so far in 2019.
- Simply Wall St.•last month
Did TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Sell Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholder...
- GlobeNewswire•last month
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma
TG Therapeutics, Inc. (TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to its phosphoinositide-3-kinase (PI3K) delta inhibitor, umbralisib (TGR-1202), for the treatment of patients with all three types of marginal zone lymphoma (MZL): nodal, extranodal, and splenic MZL. The MZL cohort of the UNITY-NHL trial is currently evaluating the safety and efficacy of single agent umbralisib in patients with MZL who have received at least one prior anti-CD20 regimen, the same indication for which the FDA recently granted breakthrough therapy designation for umbralisib.
- GuruFocus.com•2 months ago
5 Oncology Companies That Are Set to Run
The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy investor interest. Warning! GuruFocus has detected 6 Warning Signs with SGEN.
- Motley Fool•2 months ago
3 Top Biotech Stocks to Buy in April
These three biotech stocks are worth buying this month.
- Investopedia•2 months ago
TG Therapeutics Breaks Out on Positive Umbralisib Data
TG Therapeutics shares moved sharply higher after positive clinical data, but traders will be watching these key levels ahead.
- Zacks•2 months ago
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
- GlobeNewswire•2 months ago
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC) Responses were durable, with median duration.
- GlobeNewswire•2 months ago
TG Therapeutics to Present Interim Data from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the Upcoming 2019 AACR Annual Meeting
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced that interim data from the marginal zone lymphoma (MZL) cohort of the UNITY-NHL Phase 2b pivotal trial to be presented at the upcoming American Association for Cancer Research (AACR) annual meeting has an updated embargo date and time of Monday, April 1, 2019 at 8:30am ET. At that time, the abstract will be available via the AACR meeting website at www.aacr.org, and the data which will be presented during an oral session later that day (details below) will be available on the Company’s website at www.tgtherapeutics.com/publications.cfm.
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting
TG Therapeutics, Inc. (TGTX), today announced that data from the Phase 2 multicenter trial evaluating ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) has been selected for presentation at the upcoming American Academy of Neurology (AAN) annual meeting, to be held May 4 – 10, 2019 in Philadelphia, Pennsylvania. Final data from the core Phase 2 trial has been previously presented, most recently at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting in Dallas, TX. In addition to highlighting the final Phase 2 data, the AAN presentation plans to include data from the open label extension (OLE), a trial made available to any patient who completed the core Phase 2 trial allowing them to continue treatment with ublituximab.
- Zacks•2 months ago
What Makes TG Therapeutics (TGTX) a New Strong Buy Stock
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•2 months ago
TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference
NEW YORK, March 11, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire•3 months ago
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated cancers and autoimmune diseases, today announced the successful outcome of meetings held by the independent Data Safety Monitoring Boards (DSMBs) for both the UNITY-CLL trial and for the UNITY-NHL trial. Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, "We are highly encouraged that based on the progression-free survival data accumulated to date, the UNITY-CLL DSMB determined that the study was not futile and supported continuation of the trial as planned.
- Simply Wall St.•3 months ago
Those Who Purchased TG Therapeutics Shares A Year Ago Have A 57% Loss To Show For It
This month, we saw the TG Therapeutics, Inc. (NASDAQ:TGTX) up an impressive 62%. But that doesn't change the fact that the returns over the last year have been disappointing. Specifically,Read More...
